Showing results (81-90 of 125) with videos related to

Sort By:
Pageof 13
Scientific Reports|November 30, 2021
In vivo toxicity of bioreactor-grown biomass and exopolysaccharides from Malaysian tiger milk mushroom mycelium for potential future health applicationsSiti Rokhiyah Ahmad Usuldin, Wan Abd Al Qadr Imad Wan-Mohtar, Zul Ilham, et al.
Molecular Plant-Microbe Interactions : MPMI|July 31, 2026
A Clubroot Pathogen PBS3-Like Effector Manipulates Hormonal Crosstalk to Alter Root Morphology in Arabidopsis and CanolaMelaine Gonzalez-Garcia, Jiaxu Wu, Marina Silvestre Vañó, et al.
Polymers|May 27, 2023
Polysaccharides-Naturally Occurring Immune ModulatorsEmma J Murphy, Gustavo Waltzer Fehrenbach, Ismin Zainol Abidin, et al.
Journal of Biomedical Materials Research. Part A|January 10, 2025
Exploring the Synergy of Metallic Antimicrobial Agents in Ternary Blends of PHB/PLA/PCLLeonardo G Engler, Marina Della Giustina, Marcelo Giovanela, et al.
Molecular Cancer Therapeutics|October 15, 2008
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signalingScott M Wilhelm, Lila Adnane, Philippa Newell, et al.
Postgraduate Medical Journal|October 23, 2015
Clinical and diagnostic findings in patients with elevated cerebrospinal bilirubinMark O McCarron, Mark Lynch, Peter McCarron, et al.
International Journal of Pharmaceutics|July 31, 2016
Matrix and reservoir-type multipurpose vaginal rings for controlled release of dapivirine and levonorgestrelPeter Boyd, Susan M Fetherston, Clare F McCoy, et al.
Cancer Research|December 21, 2006
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5Li Liu, Yichen Cao, Charles Chen, et al.
Nature Reviews. Drug Discovery|October 4, 2006
Discovery and development of sorafenib: a multikinase inhibitor for treating cancerScott Wilhelm, Christopher Carter, Mark Lynch, et al.
International Journal of Cancer|December 21, 2010
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activityScott M Wilhelm, Jacques Dumas, Lila Adnane, et al.
Pageof 13